Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s00228-020-03032-6 http://scihub22266oqcxt.onion/10.1007/s00228-020-03032-6 33188451!7665884!33188451     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+J+Clin+Pharmacol 2021 ; 77 (4): 583-593 Nephropedia Template TP {{tp|p=33188451|t=2021. Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients |pdf=|usr=}}{{33188451}} gab.com Text Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients JO: Eur J Clin Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=33188451 #FOAvip AIMS: Chloroquine (CQ) has been repurposed to treat coronavirus disease 2019 (COVID-19). Understanding the pharmacokinetics (PK) in COVID-19 patients is essential to study its exposure-efficacy/safety relationship and provide a basis for a possible dosing regimen optimization. SUBJECT AND METHODS: In this study, we used a population-based meta-analysis approach to develop a population PK model to characterize the CQ PK in COVID-19 patients. An open-label, single-center study (ethical review approval number: PJ-NBEY-KY-2020-063-01) was conducted to assess the safety, efficacy, and pharmacokinetics of CQ in patients with COVID-19. The sparse PK data from 50 COVID-19 patients, receiving 500 mg CQ phosphate twice daily for 7 days, were combined with additional CQ PK data from 18 publications. RESULTS: A two-compartment model with first-order oral absorption and first-order elimination and an absorption lag best described the data. Absorption rate (ka) was estimated to be 0.559 h(-1), and a lag time of absorption (ALAG) was estimated to be 0.149 h. Apparent clearance (CL/F) and apparent central volume of distribution (V2/F) was 33.3 l/h and 3630 l. Apparent distribution clearance (Q/F) and volume of distribution of peripheral compartment (Q3/F) were 58.7 l/h and 5120 l. The simulated CQ concentration under five dosing regimens of CQ phosphate were within the safety margin (400 ng/ml). CONCLUSION: Model-based simulation using PK parameters from the COVID-19 patients shows that the concentrations under the currently recommended dosing regimen are below the safety margin for side-effects, which suggests that these dosing regimens are generally safe. The derived population PK model should allow for the assessment of pharmacokinetics-pharmacodynamics (PK-PD) relationships for CQ when given alone or in combination with other agents to treat COVID-19. Twit Text FOAVip Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients ????Eur J Clin Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=33188451 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33188451 #FOAvip English Wikipedia <ref>{{Cite pmid|33188451}}</ref> Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients #MMPMID33188451 Yao X; Yan X; Wang X; Cai T; Zhang S; Cui C; Wang X; Hou Z; Liu Q; Li H; Lin J; Xiong Z; Liu D Eur J Clin Pharmacol 2021[Apr]; 77 (4): 583-593 PMID33188451show ga AIMS: Chloroquine (CQ) has been repurposed to treat coronavirus disease 2019 (COVID-19). Understanding the pharmacokinetics (PK) in COVID-19 patients is essential to study its exposure-efficacy/safety relationship and provide a basis for a possible dosing regimen optimization. SUBJECT AND METHODS: In this study, we used a population-based meta-analysis approach to develop a population PK model to characterize the CQ PK in COVID-19 patients. An open-label, single-center study (ethical review approval number: PJ-NBEY-KY-2020-063-01) was conducted to assess the safety, efficacy, and pharmacokinetics of CQ in patients with COVID-19. The sparse PK data from 50 COVID-19 patients, receiving 500 mg CQ phosphate twice daily for 7 days, were combined with additional CQ PK data from 18 publications. RESULTS: A two-compartment model with first-order oral absorption and first-order elimination and an absorption lag best described the data. Absorption rate (ka) was estimated to be 0.559 h(-1), and a lag time of absorption (ALAG) was estimated to be 0.149 h. Apparent clearance (CL/F) and apparent central volume of distribution (V2/F) was 33.3 l/h and 3630 l. Apparent distribution clearance (Q/F) and volume of distribution of peripheral compartment (Q3/F) were 58.7 l/h and 5120 l. The simulated CQ concentration under five dosing regimens of CQ phosphate were within the safety margin (400 ng/ml). CONCLUSION: Model-based simulation using PK parameters from the COVID-19 patients shows that the concentrations under the currently recommended dosing regimen are below the safety margin for side-effects, which suggests that these dosing regimens are generally safe. The derived population PK model should allow for the assessment of pharmacokinetics-pharmacodynamics (PK-PD) relationships for CQ when given alone or in combination with other agents to treat COVID-19. |*COVID-19 Drug Treatment[MESH] |*Drug Repositioning[MESH] |*Models, Biological[MESH] |Administration, Oral[MESH] |Adult[MESH] |Aged[MESH] |COVID-19/virology[MESH] |Chloroquine/administration & dosage/adverse effects/*analogs & derivatives/pharmacokinetics[MESH] |Dose-Response Relationship, Drug[MESH] |Drug Administration Schedule[MESH] |Female[MESH] |Gastrointestinal Absorption[MESH] |Humans[MESH] |Male[MESH] |Metabolic Clearance Rate[MESH] |Middle Aged[MESH]Population-based meta-analysis of chloroquine: informing chloroquine (epmc).pdf DeepDyve Pubget Overpricing